Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6841 to 6855 of 7707 results

  1. Eltrombopag for untreated severe aplastic anaemia [ID1198]

    Discontinued [GID-TA10284]

    Technology appraisal guidance
    Discontinued

  2. Renal cell carcinoma - sunitinib [ID1076]

    Discontinued [GID-TA10166]

    Technology appraisal guidance
    Discontinued

  3. Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer [ID1228]

    Discontinued [GID-TA10203]

    Technology appraisal guidance
    Discontinued

  4. NGR-TNF for previously treated advanced malignant pleural mesothelioma [ID655]

    Discontinued [GID-TA10183]

    Technology appraisal guidance
    Discontinued

  5. Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer [ID1168]

    Discontinued [GID-TA10208]

    Technology appraisal guidance
    Discontinued

  6. Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423]

    Discontinued [GID-TA10330]

    Technology appraisal guidance
    Discontinued

  7. Pancreatic cancer - capecitabine [ID389]

    Discontinued [GID-TAG394]

    Technology appraisal guidance
    Discontinued

  8. Guadecitabine for untreated acute myeloid leukaemia [ID1411]

    Discontinued [GID-TA10325]

    Technology appraisal guidance
    Discontinued

  9. Ibrutinib for treating relapsed or refractory follicular lymphoma and marginal zone lymphoma [ID977]

    Discontinued [GID-TA11238]

    Technology appraisal guidance
    Discontinued

  10. Capecitabine for the treatment of advanced pancreatic cancer [ID127]

    Discontinued [GID-TA11239]

    Technology appraisal guidance
    Discontinued

  11. Pazopanib for adjuvant treatment of locally advanced renal cell carcinoma [ID1091]

    Discontinued [GID-TA11240]

    Technology appraisal guidance
    Discontinued

  12. Canakinumab and tocilizumab for treating systemic juvenile idiopathic arthritis [ID983]

    Discontinued [GID-TA11241]

    Technology appraisal guidance
    Discontinued

  13. Selumetinib for treating differentiated thyroid cancer [ID1079]

    Discontinued [GID-TA10207]

    Technology appraisal guidance
    Discontinued

  14. Everolimus for the treatment of prophylaxis of organ rejection in cardiac transplantation [ID114]

    Discontinued [GID-TAG232]

    Technology appraisal guidance
    Discontinued

  15. Nivolumab for treating recurrent glioblastoma [ID998]

    Discontinued [GID-TA10126]

    Technology appraisal guidance
    Discontinued